





UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Carole Ciolina, et. al.

Art Unit:

1645

Serial No.: 09/646,399

Filed:

November 1, 2000

Title:

Nucleic Acid Transfer Vectors,

Compositions Containing Same And Uses

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, D.C. 20231, on

SECOND REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

In the Continuing Data as Claimed by Applicant section, after THIS APPLICATION IS A 371 OF PCT/FR99/00643 03/19/1999, please insert --WHICH CLAIMS BENEFIT OF US 60/085,848 05/18/1998---.

In the Title, please delete "Nucleic Acid Transfer Vectors, Compositions Containing Same and Uses" and insert -- VECTORS FOR TRANSFERRING NUCLEIC ACIDS, COMPOSITOINS CONTAINING THEM AND THEIR USES--.

The corrections are not due to any error by Applicants and no fee is due.

Respectfully submitted,

Karen I. Krupen

Registration No. 34,647

Attorney for Applicant

Aventis Pharmaceuticals Inc. Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4658 (908) 231-2626 Telefax

ST98008A-US



KIK

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023I

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/646,399	11/01/2000	1645	1756	ST98008A	12	42	2

5487 **AVENTIS PHARMACEUTICALS PRODUCTS INC** ROUTE 202-206; MAIL STOP: EMC-G1

PO BOX 6800

BRIDGEWATER, NJ 08807

COMPUTER -0000000005554358 **ENTERED**

FILING RECEIPT

File RequesT 12/15/00

Date Mailed: 11/14/2000

PATENT DEPT

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER. FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Carole Ciolina, Paris, FRANCE: Daniel Scherman, Paris, FRANCE; Pierre Wils, Oakland, CA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/FR99/00643 03/19/1999 WHICH CLAIMS BENEFIT OF FOREIGN Applications 05/18/98 US 60/085,848

FRANCE 98/03573 03/24/1998

If Required, Foreign Filing License Granted 11/14/2000


VECTORS FOR TRANSFERRING NUCLEIC ACIDS, COMPOSIT


Nucleic acid transfer vectors, compositions containing same and uses

Preliminary Class

Title

435





LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:



Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

